<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

MD Biosciences Launches New Products Division - MD Bioproducts

Posted by MD Biosciences on Oct 6, 2009 10:45:00 AM

MD Biosciences (MDB)  launches MD  Bioproducts, a division of MD Biosciences, in a continued effort to  meet client needs for high quality research products. The new division allows MD Biosciences to strengthen and expand it's product offering for immunology and cell biology research while maintaining its contract research focus within inflammation and neurology disease research.

While MD Biosciences has offered its products for purchase since 1991, the new division permits for increased product distribution by 140 percent. Cell Culture Related Reagents, Assays, Antibodies, Proteins, and Western Blot kits are some of the products MD Bioproducts currently provides. Currently, new products and product technologies are being explored and will be added to the development and manufacturing for the coming year.

"At MD Biosciences, our top priority has always been meeting the needs of our clients through the products we offer and customer experience we deliver. The launch of MD Bioproducts is a great step of convenience for our clients-accommodating them to optimize their research process. We know that our products offer accuracy and reproducibility so our clients can be confident in their results. Our quality reagents contribute to the success of our clients' research," stated MD Biosciences President, Eddie Moradian.

Apart from the key benefit of increased manufacturing opportunities, the new division provides a better resource for product purchasers. VP of Marketing & Sales, Amy Clausen said, "MD Bioproducts showcases a new, clean look--including packaging, logo and its own website, which allows for easy navigation and viewing of product features. We are thrilled to be taking this direction at MDB as it will simplify and improve the customer experience for the client." MD Bioproducts website may be visited at www.mdbioproducts.com.


About MD Biosciences

MD Biosciences provides contract research services including efficacy testing, mode of action platforms, in vitro analysis, and histology for the Pharmaceutical, Medical Device and Animal Health & Nutrition Industries. We offer several novel models in the area of rheumatoid arthritis (RA), Multiple sclerosis, asthma, IBD, pain, and Parkinson's disease. The in-depth expertise in these disease models has been applied to designing protocols to assess the efficacy and required dosage of novel compounds. Contracted studies are designed and reviewed by MDB’s panel of internationally recognized experts and performed at one of MDB’s specialized laboratories located in St. Paul, MN (USA), Glasgow (Scotland) or in Israel. We provide a ready team of experts to tackle problems and provide solutions.

About MD Bioproducts

MD Bioproducts is a division of MD Biosciences offering high-quality reagents for immunology and cell biology research. Our goal is to provide products that are easy-to-use, accurate and reproducible – ultimately contributing to our client's research success.

###



The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.
Read More

Topics: Research Products

MD Biosciences Expands Pre-clinical Inflammatory & Neuro Drug Research

Posted by Amy Clausen on Oct 5, 2009 10:51:00 AM

MD Biosciences (MDB), a contract research organization offering pre-clinical services and products in support of drug discovery for inflammatory and neurological diseases, relocated its U.S. office from 1000 Westgate Dr, St Paul, MN to 2575 University Ave W, St Paul, MN on October 3, 2009. The new location equips MD Biosciences with more lab space, allowing for increased capacity for in vitro services and product development and manufacturing to increase product offering.

Eddie Moradian, President of MD Biosciences states, "At MD Biosciences, we have always promised our clients that we will meet their needs now and in the future; our expansion ensures that commitment. We doubled our lab space so that we are able to provide 150 percent more services and increase product development by 130 percent in the coming year in comparison with the last.

Our relocation is just one step of many in the endeavor to continue to offer the highest quality services and products in assisting our customers in meeting their objectives. Future projections include adding more highly specialized scientists to our team and increasing our focus on our available products and proprietary reagents."


About MD Biosciences

MD Biosciences provides products and pre-clinical services, which include efficacy testing, mode of action platforms, in vitro analysis, histology and imaging for the Pharmaceutical, Medical Device and Animal Health & Nutrition Industries. We offer several novel models in the area of rheumatoid arthritis (RA), Multiple sclerosis, asthma, IBD, pain, and Parkinson's disease. The in-depth expertise in these disease models has been applied to designing protocols to assess the efficacy and required dosage of novel compounds. Contracted studies are designed and reviewed by MDB’s panel of internationally recognized experts and performed at one of MDB’s specialized laboratories located in St. Paul, MN (USA), Glasgow (Scotland) or in Israel . We provide a ready team of experts to tackle problems and provide solutions. MDB also supplies for purchase by all laboratories many of the products and proprietary reagents used in our research, regardless of whether MDB is contracted as a research organization. This allows our clients to optimize their own research process by selecting steps to be performed by MDB and research to be performed in-house.




###


The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.
Read More

Topics: CRO/outsourcing

MD Biosciences Releases Tamm-Horsfall (Uromodulin) ELISA

Posted by Amy Clausen on Jul 6, 2009 1:14:00 PM


MD Biosciences, a global biotechnology company, announces the recent launch of its new Tamm-Horsfall (THP, Uromodulin) ELISA. To date, very few manufactured ELISAs are commercially available for the measurement of THP, causing researchers to spend extra time optimizing and manufacturing their own with the potential for variable results. The MD Biosciences Tamm-Horsfall ELISA kit has been optimized during development to provide precise and reproducible results. Selection of antibody pairs, careful control of microplate coating, formulation of reagents and protocol design along with stringent quality control procedures compile a completed ELISA kit that provides researchers a rapid and easy to use alternative to the do-it-yourself methods.

 

Tamm-Horsfall ELISA Specifications (Catalog # M036020):

Range of Assay: 9.375 – 150 ng/mL

Sensitivity: <5.50 ng/mL

Length of Assay: 2 hours 40 min

Sample Size: 50 uL

Precision: < 12.2 %CV for intra- and inter-assay precision

Cross-Reactivity: Human and canine urine samples

 

Tamm-Horsfall protein (THP, also known as uromodulin) is the most abundant protein found in the urine of mammals. THP is 616 amino acids in length with a molecular weight of 80 kDa, and is synthesized in the thick ascending loop of Henle. While the specific function of THP is unknown, it appears to have a role in the regulation of salt and water excretion by the kidney. Soluble THP has been found to help protect against urinary tract infections of E. coli and P. mirabilis by inhibiting the binding of the bacteria to the epithelial cells of the urinary tract. In addition, it has been suggested that THP may help prevent renal stone formation. Defects in THP are associated with human diseases such as familial juvenile hyperuricemic nephropathy (FJHN) and medullary cystic kidney disease (MCKD2).

About MD Biosciences

MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

 

###

 

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

PharmaGap & MD Biosciences Pursue Novel Inflammatory & Neuro PKC Theta Inhibitor

Posted by MD Biosciences on Mar 16, 2009 10:58:00 AM


Zurich, Switzerland & Ottawa, Canada, March 16, 2009 – PharmaGap Inc. (TSX-V: GAP)

(“PharmaGap” or “the Company”) and MD Biosciences GmbH (“MD Biosciences”) have entered into a co-development collaboration pertaining to novel compounds for therapeutic usage in inflammatory and neurological applications, including potentially arthritis and multiple sclerosis. MD Biosciences has been granted exclusive access to a series of novel peptide compounds designed by PharmaGap as inhibitors of protein kinase c theta (“PKC theta”). PKC theta is a cellular signaling molecule associated with processes believed to contribute to many inflammatory and neurological disease conditions. MD Biosciences will assess the PharmaGap compounds in order to characterize their activity against PKC theta and then identify specific disease conditions in the areas of inflammation and neurology where the compounds may prove to be of therapeutic value. MD Biosciences would act as the lead partner to then commercialize the compounds for these specific therapeutic indications. Commercialization rights on generated intellectual property will be shared by the companies. Details of the agreement remain confidential.

 

MD Biosciences is a Swiss-based preclinical contract research and drug development company with numerous technology platforms and a core focus in Inflammation and Neurology Research. The Drug Discovery division is focused on developing early stage drug compounds for therapeutic applications within inflammation and neurology. MD Biosciences’ strategy is to develop a series of novel drug compounds suitable for out-licensing to larger pharmaceutical industry partners. MD Biosciences operates facilities in Switzerland, the UK, the U.S. and Israel.

 

Dr. Eddie Moradian, Chief Executive of MD Biosciences, said, “We are extremely pleased to establish this collaboration with PharmaGap. The application of our inflammation and neurology discovery platforms to PharmaGap’s novel peptide inhibitors of PKC theta will accelerate and maximize the potential for development and future commercialization for the resulting final compounds. Our knowledge of the inflammation and neurology field tells us that novel compounds targeting protein kinases and cell signaling are of great interest to the pharmaceutical industry”

 

Dr. Jenny Phipps, Chief Scientific Officer of PharmaGap, stated, “I am delighted and excited to continue working with the technical and scientific team at MD Biosciences. I believe that their expertise and technology will add immensely to our PKC theta development program, not only in the area of inflammation and neurology but also in providing key insights that can be used in our established cancer program.”

 

“We are very pleased that MD Biosciences has identified our inhibitor of PKC theta as a compound of interest to which they wish to apply development resources and technology” said Robert C. McInnis, President and C.E.O. of PharmaGap. “Their capabilities and technology platform will allow much quicker and more technologically efficient development of a potential therapeutic drug for use in inflammation and neurological disease, which is an area in which PharmaGap has not defined as being a core focus, thus leveraging the potential value for PharmaGap shareholders in the investment in our technology platform made to date. This collaboration allows us to expand the potential downstream value of the PKC theta compound into other diseases, while allowing us to maintain our clear focus on developing compounds for cancer. Furthermore, it demonstrates the value in the underlying concept of our Company’s research program, which is to produce a series of compounds targeting PKC isoforms based on a common drug design architecture.”

Protein Kinase C Theta

The protein kinase c family of cellular enzymes modulate important biochemical and genetic-based signaling pathways in cells. PKC theta is associated with cell signaling processes in inflammatory and neurological diseases, as well as in certain cancers.

 

About MD Biosciences GmbH

MD Biosciences (www.mdbiosciences.com) is a leading preclinical contract research organization (CRO) and drug development company focused in Inflammatory and Neurology Diseases. It’s novel technologies encompass in vivo and in vitro mechanism of action platforms, in vitro compound profiling, efficacy and proof-of-concept, as well as multiple end-point readouts including biomarker/gene expression analysis, imaging capabilities and histopathology. These technologies are currently being applied across the pharmaceutical, medical device and animal health and nutrition sectors.

 

The MD Biosciences drug discovery and development activities are funded privately by the Moradian-Shasha group with the objective of value creation through the discovery of novel compounds or the repositioning of existing compounds in new applications. MD Biosciences is open towards the negotiation of collaborations in defined areas and with companies having the same ideals and objectives.

 

About PharmaGap Inc.

PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel therapeutic compounds for the treatment of cancer. PharmaGap's research platform targets cellular signalling pathways controlled by Protein Kinase C (PKC) isoforms. PharmaGap's lead drug compound, PhG-alpha-1, is in preclinical development. The Company's strategy is to out-license drug compounds to larger life sciences companies at the preclinical stage. For more information on PharmaGap please visit the Company's website at www.pharmagap.com.

 

For information relating to this Release, please contact:

 

Robert McInnis, President & CEO
PharmaGap Inc.
(613) 990-9551 bmcinnis@pharmagap.com

Dr. Eddie Moradian, President & CEO
MD Biosciences GmbH
(651) 641-2836 eddie@mdbiosciences.com

 

---------------

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of pudating and specifically disclaims any duty to update the information in this press release.

 

Read More

MD Biosciences Adds Myocardial Infarct Models to its Porfolio

Posted by Amy Clausen on Mar 4, 2009 11:03:00 AM


Wednesday, March 4, 2009, St. Paul, MN - MD Biosciences, a Preclinical Contract Research Organization (CRO), announces today that it has expanded its preclinical contract research services by launching a line of in vivo models for the study of myocardial infarct and vascular disease. These models enable the evaluation of drug treatment for myocardial infarct.
New models include:
-       Ligation induced acute cardiac infarction
-       Coil-induced acute cardiac infarction
-       Balloon-induced cardiac ischemia reperfusion
-       Multi-focal myocardial infarct
-       Induction of vascular disease

 

These models offer the flexibility of protocol design for monitoring a variety of parameters such as ECG, invasive blood pressure, SpO2, ETCO2, and PPV. Readouts offered include ECG, Echo, Angiography, cardiac MRI and blood tests for relevant parameters such as CPK. All tests are analyzed by expert cardiologists in collaboration with the Heart Institute, Sheba Medical Center of the Tel Aviv University.

The expansion of these service capabilities, along with the addition of scientific staff, indicates the stability and forward growth of the company. MD Biosciences complete services portfolio offers efficacy testing, mode of action analysis, biomarker and gene expression analysis and histopathology services. In vivo models include Collagen Induced Arthritis (CIA), Antibody Induced Arthritis, OVA-induced Asthma, DSS and TNBS induced IBD, EAE/Multiple Sclerosis, Neuropathic Pain, Nociceptive Pain, Post-operative Pain and Parkinson’s Disease. In vitro cell based services include assays for screening of inflammatory effects, cell signaling pathway screens, enzyme inhibition assays as well as molecular mode of action assays. eba Medical Center of the Tel Aviv University.

The expansion of these service capabilities, along with the addition of scientific staff, indicates the stability and forward growth of the company. MD Biosciences complete services portfolio offers efficacy testing, mode of action analysis, biomarker and gene expression analysis and histopathology services. In vivo models include Collagen Induced Arthritis (CIA), Antibody Induced Arthritis, OVA-induced Asthma, DSS and TNBS induced IBD, EAE/Multiple Sclerosis, Neuropathic Pain, Nociceptive Pain, Post-operative Pain and Parkinson’s Disease. In vitro cell based services include assays for screening of inflammatory effects, cell signaling pathway screens, enzyme inhibition assays as well as molecular mode of action assays.

About MD Biosciences
MD Biosciences is a Preclinical Contract Research Organization (CRO) providing services and products for biotech/pharmaceutical, medical device and animal health and companies engaged in inflammations & neurology research. With specialized laboratories located in Minnesota, Glasgow, and Israel, our panel of internationally recognized experts provides in-depth expertise and technologies to overcome challenges and provide total solutions to the drug discovery market.

 

--------

 

 

The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

Topics: Cardiovascular

MD Biosciences Releases Human Collagen Type I ELISA

Posted by Amy Clausen on Feb 9, 2009 11:10:00 AM


St Paul, MN February 9, 2008MD Biosciences, a global biotechnology company focused in inflammations and neurology research, announces the recent launch of its new Human Type I Collagen (CI) ELISA, Catalog # M036007, for use with cell culture supernates. The ELISA is provided with all reagents required including a pre-coated microplate eliminating the need for a 24 hour blocking incubation found with other commercially available kits. Results are achieved in under 3 hours and are sensitive, accurate and reproducible.


Human Collagen Type I ELISA Kit specifications include:

-        100 uL sample size

-        Dynamic range of 0.062 – 5 ug/mL

-        Sensitivity < 0.35 ug/mL

-        Length of assay < 3 hours

-        Crossreactivity is < 0.1% with Type II and Type IV collagen

Collagen Type I (COL1A1, COL1A2) is the most abundant protein and is found in the skin, connective tissue, tendons, ligaments, cornea, intevertebral disks, scar tissue, and lung. It has been found to be involved in many human diseases such as fibrosis, osteoporosis, cancer and artherosclerosis. It is a fibrillar collagen comprised of 3 polypeptide chains (alpha-chains), which form a unique helical structure. It is a heterotrimer of two a1(I) and one a2(I) chains. Collagen Type I molecules form cross-striated fibrils in the extracellular space, giving the tissues their mechanical strength and providing the major biomechanical scaffold for cell attachment and anchorage of macromolecules. Collagen Type I also interacts with many cells, such as fibroblasts, and with platelets during blood clotting.

 


The addition of the Human Collagen Type I assay enhances the line of collagen-related products offered by MD Biosciences, which include Collagen Type II ELISA; Anti-Collagen Type II ELISAs for IgG; IgG2a and IgG2b isotypes (see http://www.mdbiosciences.com/elisas_assays.html for a list of current ELISAs); Collagen Type II Staining kit, Bovine and Chicken Collagen Type II http://www.mdbiosciences.com/typeIICollagen.html), Collagen Antibodies and ArthritoMab Anti-Collagen Antibody Cocktail (http://www.mdbiosciences.com/ArthritoGenicMonoclonalAntibodyCocktailProduct.html)


About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

 

###

 


The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More